Put Buying Activity in Medifast (MED) Targets Downside in Shares Following Last Week's Earnings Sell-Off -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Medifast (MED) PT Lowered to $155 at Lane Research
November 11, 2019 12:49 PM ESTLane Research analyst Douglas M. Lane lowered the price target on Medifast (NYSE: MED) to $155.00 (from $170.00) while maintaining a Buy rating.
... MorePre-Open Movers 11/08: (DERM) (STMP) (DIS) Higher; (ANAB) (MED) (TDC) Lower (more...)
November 8, 2019 9:23 AM ESTToday's Pre-Open Movers
AnaptysBio, Inc. (Nasdaq: ANAB) 71.9% LOWER; announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis. Each of the etokimab dosing arms failed to meet the primary endpoint of the trial, which was demonstration of statistically greater improvement in the Eczema Area and Severity Index (EASI) relative placebo at week 16. The Company will be receiving... More
UPDATE: DA Davidson Downgrades Medifast (MED) to Neutral; 'Gone Off the Rails'
November 8, 2019 6:37 AM EST(Updated - November 8, 2019 9:38 AM EST)
(updated to add analyst comments)
DA Davidson analyst Linda Bolton Weiser downgraded Medifast (NYSE: MED) from Buy to Neutral with a price target of $74.00 (from $250.00).
The analyst commented, "MED reported disappointing 3Q19 results and... More
After-Hours Movers 11/07: (TRUE) (STMP) (DIS) Higher; (MED) (TDC) (GPS) Lower (more...)
November 7, 2019 6:26 PM ESTToday's After-Hours Movers
Medifast (NYSE: MED) 27.9% HIGHER; reported Q3 EPS of $1.32, $0.02 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $190.1 million versus the consensus estimate of $195.17 million. Medifast sees Q4 2019 EPS of $1.03-$1.13, versus the consensus of $2.05. Medifast sees Q4 2019 revenue of $157-167 million, versus the consensus of $202.33 million.
TrueCar (NASDAQ: TRUE) 25.6% HIGHER; reported Q3 EPS of $0.04, $0.07 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $90.6 million versus the consensus... More
Medifast (MED) Misses Q3 EPS by 2c, Q4 Guidance Falls Well Short of Consensus
November 7, 2019 4:28 PM ESTMedifast (NYSE: MED) reported Q3 EPS of $1.32, $0.02 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $190.1 million versus the consensus estimate of $195.17 million.
GUIDANCE:
Medifast sees Q4 2019 EPS of $1.03-$1.13, versus the consensus of $2.05. Medifast sees Q4... More
